Concepedia

James Elvecrog

JE

Statistics

Publications

7

Citations

458

H-Index

7

Active since

2016

Affiliations

Kindeva Drug Delivery (United States)(Current)

University of Washington

Infectious Disease Research Institute

University of Virginia

3M (United States)

James Elvecrog is an author at Kindeva Drug Delivery (United States) specializing in immunology, immunization, and innate immunity.

Publications per year

2016–2019

7

Publications

7

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Stefanie Mullins, John P. Vasilakos, Katharina Deschler et al. · Journal for ImmunoTherapy of Cancer · 2019 · 204 citations · Full text

, , +17

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

Neal Van Hoeven, Christopher B. Fox, Brian Granger et al. · Scientific Reports · 2017 · 86 citations · Full text

, , +17

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

Christopher B. Fox, Mark T. Orr, Neal Van Hoeven et al. · Journal of Controlled Release · 2016 · 64 citations · Full text

, , +17

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica

Mayuresh M. Abhyankar, Mark T. Orr, Susan Lin et al. · npj Vaccines · 2018 · 36 citations · Full text

, , +17

Thermosensitive Gel–Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197

Amir Fakhari, Sean Nugent, James Elvecrog et al. · Journal of Pharmaceutical Sciences · 2017 · 26 citations

, , +13

1–5 of 7